Cite
MLA Citation
M Ferrante et al.. “OWE-05 Interim long-term safety/efficacy of risankizumab treatment in crohn's disease patients from the open-label extension study.” Gut, vol. 68, no. 2, 2019, p. A64. http://access.bl.uk/ark:/81055/vdc_100135151977.0x000042